Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) FCF Margin (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed FCF Margin for 8 consecutive years, with 16.27% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 15155.0% year-over-year to 16.27%, compared with a TTM value of 2.28% through Dec 2025, up 29276.0%, and an annual FY2025 reading of 2.28%, up 29276.0% over the prior year.
  • FCF Margin was 16.27% for Q4 2025 at Zevra Therapeutics, up from 15.92% in the prior quarter.
  • Across five years, FCF Margin topped out at 138.34% in Q2 2021 and bottomed at 8581.25% in Q2 2022.
  • Average FCF Margin over 5 years is 565.63%, with a median of 131.78% recorded in 2024.
  • The sharpest move saw FCF Margin crashed -871959bps in 2022, then skyrocketed 847822bps in 2023.
  • Year by year, FCF Margin stood at 33.5% in 2021, then crashed by -479bps to 193.88% in 2022, then soared by 35bps to 125.62% in 2023, then decreased by -8bps to 135.28% in 2024, then skyrocketed by 112bps to 16.27% in 2025.
  • Business Quant data shows FCF Margin for ZVRA at 16.27% in Q4 2025, 15.92% in Q3 2025, and 14.73% in Q2 2025.